Dacarbazine and the Agonistic TRAIL Receptor-2 Antibody Lexatumumab Induce Synergistic Anticancer Effects in Melanoma
Birgit Engesæter(Norwegian Institute of Public Health), Gunhild M. Mælandsmo(Oslo University Hospital)
Cited by 15
Related Papers
Nuclear Legumain Activity in Colorectal Cancer
|PLoS ONE|2013|89
Activation of NF‐κB by extracellular S100A4: Analysis of signal transduction mechanisms and identification of target genes
|International Journal of Cancer|2008|83
Combining the oncolytic peptide LTX-315 with doxorubicin demonstrates therapeutic potential in a triple-negative breast cancer model
|Breast Cancer Research|2019|65